Tommaso Filidei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tommaso Filidei has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Marciano
Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa, 56124 Pisa, Italy
1 shared publication - Dania Cioni
Department of Radiology, Pisa University School of Medicine, Pisa, Italy
1 shared publication - Duccio Volterrani
Nuclear Medicine Unit, Department of Translational Research and of New Surgical and Medical Technology, University of Pisa, 56126 Pisa, Italy
1 shared publication - Emanuele Neri
Academic Radiology, Department of Translational Research and of New Surgical and Medical Technology, University of Pisa, 56126 Pisa, Italy
1 shared publication - Francesca Pia Caputo
Department of Translational Research, Academic Radiology, University of Pisa, 56126 Pisa, Italy
1 shared publication - Gayane Aghakhanyan
Nuclear Medicine Unit, Department of Translational Research and of New Surgical and Medical Technology, University of Pisa, 56126 Pisa, Italy
1 shared publication
Latest Publications
- Open Access
- 17 April 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (8) , 832
Advancing Pediatric Sarcomas through Radiomics: A Systematic Review and Prospective Assessment Using Radiomics Quality Score (RQS) and Methodological Radiomics Score (METRICS)
Pediatric sarcomas, rare malignancies of mesenchymal origin, pose diagnostic and therapeutic challenges. In this review, we explore the role of radiomics in reshaping our understanding of pediatric sarcomas, emphasizing methodological considerations and applications such as diagnostics and predictive modeling. A systematic review conducted up to November 2023 identified 72 papers on radiomics analysis in pediatric sarcoma from PubMed/MEDLINE, Web of Knowledge, and Scopus. Following inclusion and exclusion criteria, 10 reports were included in this review. The studies, predominantly retrospective, focus on Ewing sarcoma and osteosarcoma, utilizing diverse imaging modalities, including CT, MRI, PET/CT, and PET/MRI. Manual segmentation is common, with a median of 35 features extracted. Radiomics Quality Score (RQS) and Methodological Radiomics Score (METRICS) assessments reveal a consistent emphasis on non-radiomic features, validation criteria, and improved methodological rigor in recent publications. Diagnostic applications dominate, with innovative studies exploring prognostic and treatment response aspects. Challenges include feature heterogeneity and sample size variations. The evolving landscape underscores the need for standardized methodologies. Despite challenges, the diagnostic and predictive potential of radiomics in pediatric oncology is evident, paving the way for precision medicine advancements.
- 17 April 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (8) , 832
Open AccessAdvancing Pediatric Sarcomas through Radiomics: A Systematic Review and Prospective Assessment Using Radiomics Quality Score (RQS) and Methodological Radiomics Score (METRICS)
Pediatric sarcomas, rare malignancies of mesenchymal origin, pose diagnostic and therapeutic challenges. In this review, we explore the role of radiomics in reshaping our understanding of pediatric sarcomas, emphasizing methodological considerations and applications such as diagnostics and predictive modeling. A systematic review conducted up to November 2023 identified 72 papers on radiomics analysis in pediatric sarcoma from PubMed/MEDLINE, Web of Knowledge, and Scopus. Following inclusion and exclusion criteria, 10 reports were included in this review. The studies, predominantly retrospective, focus on Ewing sarcoma and osteosarcoma, utilizing diverse imaging modalities, including CT, MRI, PET/CT, and PET/MRI. Manual segmentation is common, with a median of 35 features extracted. Radiomics Quality Score (RQS) and Methodological Radiomics Score (METRICS) assessments reveal a consistent emphasis on non-radiomic features, validation criteria, and improved methodological rigor in recent publications. Diagnostic applications dominate, with innovative studies exploring prognostic and treatment response aspects. Challenges include feature heterogeneity and sample size variations. The evolving landscape underscores the need for standardized methodologies. Despite challenges, the diagnostic and predictive potential of radiomics in pediatric oncology is evident, paving the way for precision medicine advancements.